摘要
目的:观察糖肾宁合剂治疗糖尿病肾病(DN)的临床疗效。方法:将84例DN患者随机分为2组。治疗组43例,在糖尿病基础治疗同时服糖肾宁合剂;对照组41例,只予糖尿病基础治疗。观察治疗前后临床症状体征、空腹血糖(FBG)、24小时尿白蛋白(Alb)、尿β_2-微球蛋白(β_2-MG)、血浆血栓素B_2(TXB_2)、6-酮-前列腺素F_(1α)(6-K-PGF_(1α))、T/K比值、α-颗粒膜蛋白140(GMP140)、过氧化脂质(LPO)等变化。结果:治疗组症状体征积分明显减少,FBG、24小时尿Alb、尿β_2-MG、血浆TXB_2、GMP140、T/K、LPO等均明显下降,6-K-PGF_(1α)升高(P<0.01,P<0.05)。而对照组除症状体征积分及FBG有改变外,其余指标变化不显著。结论:糖肾宁合剂能改善DN高凝状态,调节TXA_2/PGI_2平衡,抑制脂质过氧化反应,延缓DN发展。
Objective: To observe the curative effect of Tangshen-ning Mixture (TM) for diabetic nephrosis (DN). Methods: 84 cases of DN were allocated randomly to treatment group (43 cases treated by basic treatment + TM) and control group (41 cases treated by basic treatment alone) . Symptoms and signs, fasting blood glucose (FBG), 24h urine albumin (Alb), urine β2-microglobulin (β2-MG), plasma thromboxane B2(TXB2), 6-Keto-prostaglandin F1α (6-K-PGF1α), α-granular membrane protein 140 (α-GMP 140) and lipid peroxide (LPO) were determined before and after treatment. Results: In treatment group, the scoring of symptoms and signs were markedly reduced, FBG, 24h urine Alb, (β2-MG, plasma TXB2, α-GMP140, T/K and LPO were markedly decreased , but 6-K-PGFα was increased (P<0.01, P<0.05) .In control group, except the scoring of symptoms and signs and FBG, the changes of other indexes were not obvious. Conclusion: TM can improve the hypercoagulability of DN, regulate the balance of TXA2/ PGI2, inhibit lipid peroxidation and delay the progress of DN.
出处
《新中医》
CAS
北大核心
2002年第12期37-38,共2页
New Chinese Medicine
